Health & Fitness
Health and Fitness
Health and Fitness
Wed, March 18, 2009Tue, March 17, 2009Mon, March 16, 2009Sun, March 15, 2009Fri, March 13, 2009Thu, March 12, 2009Wed, March 11, 2009Tue, March 10, 2009Mon, March 9, 2009Fri, March 6, 2009Thu, March 5, 2009Wed, March 4, 2009Tue, March 3, 2009Mon, March 2, 2009Fri, February 27, 2009Thu, February 26, 2009Wed, February 25, 2009Tue, February 24, 2009Mon, February 23, 2009Sun, February 22, 2009Fri, February 20, 2009Thu, February 19, 2009Wed, February 18, 2009Tue, February 17, 2009Zacks Industry Outlook Highlights: Immucor
Published in Health and Fitness on Wednesday, February 25th 2009 at 3:15 GMT, Last Modified on 2009-02-25 03:16:30 by Market Wire
CHICAGO--([ BUSINESS WIRE ])--Zacks.com releases the latest Industry Outlook. Today's interview is with senior analyst Tom Park,who talks about the Medical Devices Industry, including Immucor (Nasdaq: BLUD).
A synopsis of today's Industry Outlook is presented below. The full article can be read at [ http://at.zacks.com/?id=2678 ].
As a result of the continued problems in controlling healthcare costs, we expect demand for products in the diagnostic testing market to continue to grow. The diagnostic testing market is highly labor intensive and time consuming.
Many companies like Immucor (Nasdaq: BLUD) seek to automate the process or reduce diagnostic testing time, which is expected to reduce testing costs, patient care costs, and improve test accuracy. Thus, technological advances in diagnostic testing from R&D investments can play a role in helping to reduce healthcare costs and improve the quality of care.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting [ http://at.zacks.com/?id=2679 ].
About Zacks
The performance of the Zacks Rank portfolios shown above for annual and year-to-date periods are the linked monthly total returns (price changes + dividends) of equal weighted hypothetical portfolios, consisting of those stocks with the indicated Zacks Rank, assuming monthly rebalancing and zero transaction costs. These are not the returns of actual portfolios. The hypothetical portfolios were created at the beginning of each month from Jan 1988 forward based on the values of the Zacks Rank available to Zacks' clients before the beginning of each month.
The portfolios created monthly from 1988 through September 2006 exclude ADRS and are comprised of stocks that have the indicated Zacks Rank and were covered by at least two analysts at the time of the stocks inclusion in the portfolio. Starting in October 2006 and going forward, the portfolios are comprised of all stocks with the indicated Zacks Rank and do not exclude ADRs, which is more reflective of the list of stocks that customers will find on the Zacks web sites. 2007 returns are for the period of Jan 1 – Jun 30, 2007. These performance numbers have been audited from 1995 through 2003 by Autschuler Melovan, a division of American Express Financial.
